06 Oct 2013 Posted in ABPI statement By Press Office
The ABPI Board of Management reviews the Code and its operation periodically to ensure that it is addressing all issues in the environment and the changing role of external stakeholders.
The Board of Management will seek to make recommendations of changes for inclusion in a new Code that will be dated 1 January 2015. Any planned changes will be the subject of the usual consultation and would need to be agreed at the ABPI members’ meeting (November 2014).
Additional to this review, the implementation of the EFPIA Disclosure Code which covers certain payments to healthcare professionals and healthcare organisations is ongoing. A new ABPI Code to reflect this will be dated 1 January 2014 with a transition period.
Commenting on the review, Stephen Whitehead, Chief Executive of the ABPI, said:
"The review of the Code of Practice is an important step in ensuring that the industry has clear guidance for interactions and partnership at a time when the UK environment is changing significantly. Within the health sector, we have seen the major NHS reforms and the growing influence of public health bodies. We have also seen the growing weight of health technology assessment in the UK, the dynamism of digital and social media and the welcomed enhanced role of patient organisations and the public. The ABPI Code is flexible and able to respond to changing external requirements and this review will ensure that industry is in the best possible position to deal with the new environment it faces.
"The ABPI Code of Practice is, rightly, one of the most respected self-regulatory codes operating in the world today, and has provided a benchmark of best practice for other trade associations. It is one of the cornerstones in supporting and enhancing the industry’s reputation."
ABPI Press Office
Tel: +44 (0) 20 7747 1441 or +44 20 7747 1410
Mobile: +44 (0) 7808 641811 or +44 7850 312064
About the code
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.